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TransgenicMany proteins that are implicated in human disease are posttranslationally modiﬁed. This includes the
microtubule-associated protein tau that is deposited in a hyperphosphorylated form in brains of Alzheimer's
disease patients. The focus of this review article is on the physiological and pathological phosphorylation of
tau; the relevance of aberrant phosphorylation for disease; the role of kinases and phosphatases in this
process; its modeling in transgenic mice, ﬂies, and worms; and implications of phosphorylation for
therapeutic intervention.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The Alzheimer's disease (AD) brain is characterized by massive
neuronal and synaptic loss at speciﬁc predilection sites [1]. Together
with tau-containing neuroﬁbrillary tangles (NFTs) and β-amyloid
(Aβ) plaques, they are the deﬁning histopathological hallmarks of AD.
Neuroﬁbrillary lesions are found in cell bodies and apical dendrites as
NFTs, in distal dendrites as neuropil threads, and in the abnormal
neurites that are associated with some β-amyloid plaques (neuritic
plaques) [2]. NFTs are also abundant, in the absence of overt plaques,
in certain subsets of frontotemporal dementia (FTD) and other
tauopathies [3]. The neuroﬁbrillary lesions contain aggregates of the
microtubule-associated protein tau that in the course of disease is
redistributed from the mainly axonal to the somatodendritic com-
partment of neurons [4]. In tauopathies such as progressive supra-
nuclear palsy (PSP) or corticobasal degeneration (CBD), tau forms
aggregates also in non-neuronal cells [5].
Tau is a phosphoprotein owing to its unusually high serine and
threonine content. Under pathological conditions, tau is hyperpho-+61 2 9351 0731.
ll rights reserved.sphorylated, meaning that it is phosphorylated to a higher degree at
normal, physiological sites, and at additional “pathological” sites [6]
(Fig. 1). Phosphorylation of tau tends to dissociate it from micro-
tubules. Tau also undergoes a conformational change which may
assist in differential phosphorylation, and vice versa [7].
The MAPT (microtubule-associated protein tau) gene encoding tau
is located on human chromosome 17q21; in the central nervous
system it contains 15 exons, with the major tau protein isoform being
encoded by 11 exons [8]. By alternative mRNA splicing of exons 2, 3,
and 10, six major tau isoforms are produced in the adult human brain.
They differ by the presence or absence of one or two short inserts in
the amino-terminal half (0N, 1N, or 2N, respectively), and have either
three or four microtubule-binding repeat motifs in the carboxy-
terminal half (3R or 4R) (Fig. 1). In contrast to humans, mice express
only four-repeat tau isoforms (4R0N, 4R1N, or 4R2N) [9].
In AD, no mutations were found in the MAPT gene; these were
identiﬁed in FTD with Parkinsonism linked to chromosome 17 (FTDP-
17) [10–12] (Fig. 1). This established that dysfunction of tau in itself
can cause neurodegeneration and lead to dementia. In a subgroup of
FTD, termed FTLD-U (frontotemporal lobar degeneration with
ubiquitin-immunoreactive lesions) or FTDU-17, tau-negative, ubiqui-
tin-positive lesions are prominent. In these patients, mutations were
found in the PGRN gene encoding progranulin, a growth factor
Fig. 1. Themicrotubule-associated protein tau. (A) Tau is composed of an amino-terminal projection domain, amicrotubule-binding domain (MBD), and a carboxy-terminus. Human
brain expresses six major tau isoforms. They differ by the presence or absence of one or two 29 amino acid inserts (E2, E3) in the amino-terminal half (0N, 1N, or 2N, respectively),
and have either three or four microtubule-binding repeat motifs in the carboxy-terminal half (3R or 4R). (B) Until today, 42 pathogenic exonic and intronic mutations have been
identiﬁed in theMAPT gene encoding tau. Most of the exonic mutations are clustered around the MBD. Of these mutations, several have been expressed in transgenic mice including
N279K, ΔK280, G272V, P301L, P301S, V337, and R406W. (C) Selected phospho-epitopes mentioned in this review are shown for clarity along with the name of the phospho-tau-
speciﬁc antibody. Note: These phospho-epitopes are conserved between humans and mice.
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ing tumorigenesis [13,14]. It was found that the TAR DNA-binding
protein of 43 kDa (TDP-43) is a primary constituent of the ubiquitin-
positive inclusions in FTLD-U and amyotrophic lateral sclerosis [15].
Under pathological conditions, TDP-43 is, similar to tau, hyperpho-
sphorylated, ubiquitinated, and carboxy-terminally truncated [16].
2. Serine- and threonine-directed phosphorylation of tau
Of all posttranslational modiﬁcations, protein phosphorylation in
general receives special attention as it is an important cellular
regulatory mechanism [6]. It determines enzymatic activity, protein
stability, folding properties including protein aggregation, binding ofother bio-molecules, and subcellular localization. Phosphorylation
occurs mainly on serine, threonine, and tyrosine residues, although
proteins can be phosphorylated also on histidine, lysine, and arginine
residues. Phosphorylation depends on a balanced interplay between
kinases and phosphatases that is disturbed under pathological
conditions. Phosphorylation can also be affected by O-glycosylation
since some serine and threonine residues can either be O-glycosylated
or phosphorylated [17–20].
2.1. Phosphorylation of normal, fetal and ‘PHF’-tau
Tau is a phosphoprotein with a remarkably high number of
potential phosphorylation sites. The longest human tau isoform in
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followed by prolines (so-called SP/TP-sites). A KXGS motif is found in
each microtubule-binding domain making this site a substrate of
MARK kinase [21]. In addition, there are four tyrosine residues [6].
Overall, 20% of the protein is composed of amino acids that can be
potentially phosphorylated. Therefore, it is no surprise that differen-
tial phosphorylation of tau is crucial for its physiological and
pathological activities. It is then also logical that phosphorylation of
tau within themicrotubule-binding domain (e.g., at the KXGSmotives
recognized by an antibody such as 12E8 speciﬁc for pSer262/
pSer3561, see below) has functional consequences that are different
from those of phosphorylation of tau within the ﬂanking sequences
(Fig. 1).
Fetal brain contains only 3R tau that is phosphorylated at more
sites than tau from adult brain (that contains an equal mix of 3R and
4R tau), implying selective dephosphorylation of the short isoforms
during brain maturation [22]. In the developing axon, tau forms a
smooth proximo-distal phosphorylation gradient: Tau in the soma,
immature dendrites and the proximal axon is phosphorylated up to
80% at the tau-1 antibody site (Ser198/Ser199/Ser202 based on
htau40), compared to only 20% in the axonal growth cone [23,24].
In the AD brain, tau is hyperphosphorylated meaning that it is
phosphorylated to a higher degree at physiological sites as well as, in
addition, pathological sites (Fig. 1). This tau associates to form paired
helical ﬁlaments (PHFs) within NFTs. Thus pathologically phosphor-
ylated tau is also called “PHF”-tau [25,26]. Pathological sites include
pSer422, pThr212/pSer214 (AT100), and pThr231/pSer235 (recog-
nized by the conformation- and phosphorylation-dependent antibody
PHF-27/TG3, as well as AT180) [7,27–29]. Luckily, the tau research
community early on beneﬁted from an excellent collection of epitope-
speciﬁc antibodies although in recent years the costs for some
commercial antibodies have become exorbitantly high (Fig. 1).
Compared to normal tau, PHF-tau displays a reduced electropho-
retic mobility reﬂecting an increased phosphorylation state. As
phosphorylation of ‘PHF’-tau is very heterogeneous, it runs as a
smear on SDS–PAGE gels [30–34]. Upon dephosphorylation, the smear
can be resolved into discrete bands of a reducedmobility. PHF-tau also
has a lower range of pI values, indicating that it is more negatively
charged than normal tau [35]. It has a reduced capacity to bind tubulin
and to promote the polymerization and stabilization of microtubules.
Upon dephosphorylation, PHF-tau binds to tubulin in a manner that is
identical to that of normal tau [36,37]. Using mass spectrometry and
phospho-speciﬁc antibodies, an increasing number of potential
phosphorylation sites have been conﬁrmed in the AD brain, suggest-
ing that as many as 45 of the 84 possible sites of tau are
phosphorylated in PHF-tau, compared to 15 in control and up to 20
in fetal brain [38–43]. Obviously, there may be sites that have been
missed due to a lack of sensitivity [43]; however, the question is
whether these additional phospho-sites are relevant for disease
initiation and/or progression.
Many phosphorylation sites have been conﬁrmed with phospho-
rylation-dependent and epitope-speciﬁc anti-tau antibodies (Fig. 1).
This assisted in correlating differential phosphorylation with disease
progression. It was shown that in the pre-NFT state, when tau has not
yet formed ﬁlaments, neurons were stained speciﬁcally with antibody
TG3 (conformational and pThr231/pSer235-speciﬁc), and the phos-
phorylation-dependent antibodies pSer262 and pThr153. Intracellular
NFTs were most prominently stained with antibodies against pSer46,
pThr175/pThr181, pSer214, pSer262/pSer356 (12E8), and pSer422,
whereas extracellular NFTs, the so-called ghost tangles, were most
prominently stained with the AT8 (pSer202/pThr205), AT100
(pThr212/pSer214), and PHF-1/AD2 (pSer396/pSer404) antibodies,
which also stain intraneuronal NFTs. The different states of tau1 For clarity, subsequently ﬁrst the phosphorylated tau epitope (pS202 or S202) is
listed followed by the phospho tau-speciﬁc antibody in brackets.phosphorylation associated with the different stages in the progres-
sion of the disease suggest a sequential phosphorylation process
which ultimately leads to NFT formation [44]. Sequential phospho-
rylation is also evident with regards to individual phospho-epitopes.
For example, the AT100 epitope is generated in vitro by sequential
phosphorylation, ﬁrst of Ser199, Ser202, and Thr205 (ﬂanking the
AT8 epitope), then of Thr212 (by GSK-3β), and ﬁnally of Ser214
(by PKA) [45].
3. Tyrosine-directed phosphorylation of tau
Tau in NFTs is also phosphorylated at tyrosine residues (Fig. 1).
There are only 4 tyrosines in tau compared to 80 serines and
threonines, which may reﬂect the relative importance of tyrosine
phosphorylation in physiological and pathological functions, as well
as the low number of studies. As for the Ser/Thr-epitopes, there are
speciﬁc antibodies for the Tyr epitopes (reviewed in [6]). c-Abl has
been suggested as a candidate kinase for Tyr394 phosphorylation, a
site phosphorylated in both fetal and PHF-tau [46].
Tyrosine phosphorylation plays a pivotal role in the association of
tau with the plasma membrane, which is mediated by the amino-
terminal projection domain of tau [47]. Association of tau with the
plasma membrane may play a crucial role in relaying extracellular
signals. With its proline rich sequences in the amino-terminus, tau
interacts with the SH3 domains of the tyrosine kinase Fyn that
phosphorylates tau at Tyr18 [48,49]. In a study that goes far beyond
the mapping of phosphorylation sites, Bhaskar and colleagues
addressed the question why an altered ratio of 3R to 4R tau might
cause disease in FTD [50]. They used the surface plasmon resonance
biosensor technique on a panel of tau constructs and found that the
interaction between the SH3 domain of Fyn and 3R-tau was 20-fold
higher than that for 4R-tau. In addition, the afﬁnity between 4R-tau
and Fyn SH3 was increased 25- to 45-fold by phosphorylation-
mimicking mutations or by FTDP-17 mutations, supporting a role for
the Fyn–tau interaction in neurodegeneration [50].
4. Tau phosphorylation in tau transgenic mice
Classical transgenic approaches continue to be instrumental in
dissecting pathogenic mechanisms and testing therapies for AD and
FTD [51,52]. There are reports, however, of viral delivery, such as with
the Sindbis virus which was employed to express tau in selected
hippocampal sites, inducing a pathological conformation of tau as
shown by Alz50/MC1-reactivity, which caused an accumulation of
insoluble tau and induced a region-speciﬁc neurodegeneration [53].
The ﬁrst published tau transgenic mouse model expressed the
longest human four-repeat (2N4R) tau isoform under control of the
neuron-speciﬁc human Thy1 promoter [54]. Reﬂecting the approxi-
mately 10-fold lower levels of human relative to endogenous murine
tau, the phosphorylation-speciﬁc anti-tau antibodies AT8 and PHF-1/
AD2 revealed strongly labeled neurons in many brain areas, but their
numbers were small. However, as in the AD brain, tauwas re-localized
to the somatodendritic domain, in addition to tau's physiological
axonal localization. Gallyas silver impregnation failed to reveal tau
ﬁlament and NFT formation, and tau staining appeared homogenous
or, at the most, granular [54]. A comparable tau phenotype was
achieved in mice which expressed the shortest human tau isoform,
using the murine 3-hydroxy-methyl-glutaryl CoA reductase promot-
er. Here, tau was phosphorylated at the AT180 (pThr231/pSer235),
AT270 (pThr181), AD2 (pSer396/pSer404), 12E8 (pSer262/pSer356),
but not the AT8 (pSer202/pThr205) epitopes [55] (Fig. 1).
Subsequently, a more advanced phenotype was achieved in three
wild-type tau transgenic strains, by choosing better expression
vectors [56–58]. Tau was found to be phosphorylated at several
phospho-epitopes, but NFTs did not develop until the mice reached a
very old age [59]. In all three mouse strains, neuroﬁlament-containing
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axonal dilatations. Orthograde fast axonal transport was reduced as
the mice developed a progressive motor phenotype [56]. Phospho-
rylation of tau was analyzed inmore detail in one of the strains, ALZ17,
where it turned out to be compartmentalized [60]. In the axons of CA1
pyramidal neurons, tau was speciﬁcally phosphorylated at the AD2
epitope PSer396/pSer404, concomitant with increased levels of
cyclin-dependent kinase-5 (cdk5). In contrast, the 12E8 (pSer262/
pSer356) and AT180 (pThr231/pSer235) epitopes were speciﬁcally
phosphorylated in dendrites, and co-localized with increased levels of
GSK-3β [60]. Kinase activities have also been monitored in htaumice,
which express genomic wild-type tau (the 8c line [61]), on a tau
knockout background [62]. The authors found a signiﬁcant correlation
between speciﬁc phosphorylation changes and the amount of
aggregated tau. In the htau line, but not in non-NFT-forming control
mice, there were increased levels in phosphorylated (i.e., activated)
p38 and the neuronal cdk5 activators, p35 and p25, with aging, which
in turn phosphorylate tau. Changes in tau kinases in the htau mice
correlated with the amount of tau present in abnormal conformations
and with insoluble tau [63]. Together this shows that tau is subject to
differential phosphorylation, due to differential activities and com-
partmentalization of kinases and phosphatases.
The tau ﬁeld experienced a major advance with the identiﬁcation
of both exonic and intronic mutations in theMAPT gene encoding tau
in FTDP-17, a familial dementia related to AD [10–12]. The mutations
affect the ratio of 3R to 4R tau isoforms and the propensity of tau to
form ﬁbrils. By expressing FTDP-17 mutant tau in transgenic mice,
many models were established that represented NFT formation in
both neuronal and glial cells [64,65]. The transgenic models were
examined using transcriptomic and proteomic technology, including
the assessment of posttranslational modiﬁcation [66–70], and they
were subjected to behavioral analyses [71,72]. Phosphorylation
patterns, however, are difﬁcult to compare as each laboratory uses
its own set of phospho-tau-speciﬁc antibodies [5]. In P301S mutant
tau transgenic mice, neuronal loss was more pronounced than in the
P301L tau models, consistent with the early onset of FTD in patients
carrying the P301S mutation [73]. In the P301S mice, the largest
number of stained neurons was observed with AT8, followed by
AP422 (pSer422), AT180 (pThr231/pSer235), and PG5 (pSer409)
[73]. Fewer neurons were labeled by AT100 (pThr212/pSer214) and
CP3 (pSer214), with the smallest number of neurons being stained by
12E8 (pSer262/pSer356) and PHF-1 (pSer396/pSer404). Western
blotting of perchloric acid-soluble tau demonstrated that the human
tau band was strongly immunoreactive with all tested antibodies, but
AT100 (pThr212/pSer214) and CP3 (pSer214). In contrast, sarkosyl-
insoluble human tau protein reacted with all phosphorylation-
dependent anti-tau antibodies, including AT100 and CP3. This
indicates that immunoreactivity for pSer214 (part of epitope
AT100) closely mirrors the presence of ﬁlaments, suggesting that
phosphorylation of this site occurs in the course of, or after, ﬁlament
assembly. The ﬁrst P301L transgenic strain generated, JNPL3, is
characterized by a pronounced motor phenotype that is not seen in
the related P301L transgenic pR5 mice [74,75].
When we monitored NFT formation and tau phosphorylation in
these pR5 mice for up to 24 months of age we found that NFTs ﬁrst
appeared in the amygdala at 6 months, while at 24 months the only
other site with overt NFTs was the CA1 region of the hippocampus
[76]. A histological analysis revealed an increase in phosphorylation at
the AT180 (pThr231/pSer235), AT270 (pThr181), and 12E8
(pSer262/pSer356) epitopes with aging while the AT8 (pSer202/
pThr205) and pS422 epitopes behaved differently. Firstly, whereas
AT8 reactivity was found in both the soma and dendritic branch of
CA1 pyramidal neurons, pS422 staining was more conﬁned to the
soma. Secondly, numbers of AT8-positive neurons increased from 3 to
6 months of age, but at 20 months of age, the only neurons left with
AT8-reactivity were those which had undergone NFT formation. Incontrast, pS422-reactivity came up only late and concomitantly with
NFT formation [76]. As far as the disappearance in our pR5mice of the
AT8 epitope in all but NFT-bearing neurons is concerned, one
explanation may be that with advanced pathology, neurons learn to
cope with AT8 phosphorylation and the activities of the kinase and/or
phosphatase regulating phosphorylation of this epitope become
balanced resulting in a zero net phosphorylation at this epitope
[6,77]. This balancing act seems to be speciﬁc for the AT8 epitope and
the enzymes governing its phosphorylation, as other epitopes such as
AT180 or AT270 continue to be phosphorylated. In NFT-bearing
neurons, however, the AT8 phospho-epitope becomes stabilized
suggesting that either a tau phosphatase may not be able to access
the phosphorylation site or the kinase/phosphatase equilibrium in
the dysfunctional neuron may be out of balance. Our AT8 ﬁndings are
supported by data in P301S transgenic mice which, although analyzed
only until 6 months of age, reveal an increased pS422, AT8, and AT180
phosphorylation in RIPA-extracted brains that peaks at 4–5 months
and then declines signiﬁcantly at 6 months. This decline was not seen
with AT270 or phosphorylation-independent tau antibodies [78]. The
authors state that the reduction at 5 months was particularly marked
for the AT8 epitope [78]. The importance of both the AT8 and pS422
epitope in tauopathies is also demonstrated by the fact that in both
the JNPL3 and the rTg4510 strain discussed below, a 170 kDa band
linked to clinical features was preferentially detected by AT8 and
pS422, and this, possibly oligomeric, species negatively correlated
with memory [79].
To determine whether NFTs are central to the neurotoxic cascade
in AD or represent a protective neuronal response, P301L transgenic
rTg4510 mice were generated [80]. Here, transgene overexpression
could be reduced by adding doxycycline to the drinking water [80].
Despite the fact that even under suppressed conditions tau levels
were higher than what is generally achieved by conventional
transgenic approaches, memory function recovered and number of
neurons stabilized, while NFTs continued to accumulate under these
conditions. These data show that dysfunction of tau impairs memory,
whenmutant tau is massively overexpressed. They further imply that
soluble tau rather than NFTs themselves are neurotoxic [80]. Tau
phosphorylation in the rTg4510 brain was addressed in an accom-
panying paper, monitoring the mice from 1.3 to 8.5 months of age
[81]. Differences were found between the hippocampus and cortex as
AT8 reactivity was preceded by TG3 in the hippocampal CA1 region in
an order which is opposite to that found in the cortex. In the CA1
region the epitopes appeared in the following order: CP13 (pSer202),
MC1 (conformational), and TG3 (conformational and pThr231/
pSer235) at 1.3 months, followed by PG5 (pSer409), AT8 (pSer202/
pThr205), PHF-1 (pSer396/pSer404), followed by Bielschowsky
reactivity at 4–5.5 months. For the cortex, MC1, CP-13, AT8, and
PHF-1 appeared ﬁrst, followed by TG3, PG5, and Bielschowsky
reactivity [81]. This appearance of phosphorylation sites raises the
question as to whether for tau to aggregate there needs to be a
speciﬁc order of phosphorylation events, an issue discussed below in
more detail.
An interesting model of the speciﬁc phosphorylation proﬁle that
characterizes Pick's disease is the K3 strain that expresses human tau
carrying the FTD mutation K369I [82]. K3 mice develop a progressive
histopathology that is reminiscent of human FTD with the K369I
mutation [83]. Speciﬁcally, as in human Pick's disease [84] and in the
human K369I patient where the tau-containing Pick bodies are 12E8
(pSer262/pSer356)-negative [83], K3 mice also develop ovoid tau
inclusions that are 12E8-negative, while additional phospho-epitopes
of tau (as in humans) are strongly phosphorylated [82]. K3 mice show
an early-onset memory impairment and amyotrophy, in the absence
of overt neurodegeneration. However, as the mice age, neurodegen-
eration becomes evident. Different from our previously generated tau
transgenic strains, the K3mice express the transgene in the substantia
nigra (SN) and show an early-onset motor phenotype that reproduces
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instability. Interestingly, motor performance of young but not old K3
mice improved upon L-dopa treatment, which bears similarities to
Parkinsonism in FTD. The early-onset symptoms in the K3 mice are
mechanistically related to selectively impaired anterograde axonal
transport of distinct cargos, which precedes the loss of dopaminergic
SN neurons that occurs in aged mice [82]. The impaired axonal
transport in SN neurons affects, among others, vesicles containing the
dopamine-synthesizing enzyme tyrosine hydroxylase (TH) [82]. We
found that phosphorylated tau interacts pathologically with the
kinesin-associated adapter protein JIP1 both in the mice and in AD
brain [82,85]. We proved that phosphorylation of tau is required for
this pathogenic effect [85] suggesting a pathological interaction of JIP1
and phosphorylated tau as a general pathomechanism in tauopathies
including AD.
Using an elegant stereotaxic injection approach, tau toxicity was
shown to bear resemblance to prions and to spread through the brain
[86]. The study used two mouse strains: ALZ17mice that express high
levels of wild-type human tau but reveal only a modest pathology:
amyotrophy in the absence of obvious neuronal cell loss and, despite a
massive hyperphosphorylation of tau, no formation of NFTs [58,60]. In
contrast, P301Smice express, at levels comparable to the ALZ17mice,
a mutant form of tau found in familial cases of FTD; the mice present
with a particularly robust phenotype, characterized by neurodegen-
eration in the spinal cord and an abundance of NFTs [73]. When
diluted brain extracts from 6-month-old P301S mice were intracere-
brally injected into 3-month-old ALZ17 mice and the injected mice
were analyzed up to 15 months post-injection, NFT formation was
found as revealed by Gallyas silver impregnation, and reactivity with
antibody AT100 (pThr212/pSer 214).
Interestingly, Clavaguera and colleagues found that Gallyas
reactivity (i.e., NFT formation) was not conﬁned to the site of
injection, but rather induced up to 2 mm distant of the injection site
[86]. A time-course analysis suggests a stereotypical mode of
spreading (a feature characteristic of AD). Another remarkable ﬁnding
was that insoluble rather than soluble tau was responsible for the
induction of a tau pathology. Also, induction of the tau pathology
seemed to be mediated by oligodendroglia (a cell type not affected by
tau pathology in the parental P301S mice).
Additional tau transgenic models have been discussed by us in
detail elsewhere [5,65,87]. Taken together, tau transgenicmodels have
proven in vivo that the presence of familial FTD-associated tau
mutations causes tau hyperphosphorylation, aggregation, nerve cell
dysfunction, as well as neuronal and glial cell loss. They have revealed
that a glial tau pathology can affect neuronal functioning and that a tau
pathology in general causes behavioral impairment [88]. Finally, the
models highlight distinct phosphorylation sites such as pS422,
pThr212/pSer214 (AT100), pThr231/pSer235 (TG3), and pSer202/
pThr205 (AT8) in disease initiation and progression and, hence,
provide ameans to target distinct kinases for therapeutic intervention.
5. Tau phosphorylation in kinase transgenic mice
In principal, tau phosphorylation can be brought about by the
upregulation of kinases, the downregulation of phosphatases, or both.
A major question asked in the ﬁeld is which kinase(s) and
phosphatase(s) in brain bring about the pathological changes that
characterize AD-tau and how these are related to neuronal demise.
The human genome encodes a total of 516 protein kinases, with
numbers comparable in mice. Of these kinases, several have been
identiﬁed as potential tau kinases, mostly by in vitro assays incubating
recombinant tau protein with the respective kinases. These include
GSK-3β; Cdk5; the MAP kinases JNK, ERK, and p38; MARK; CK2;
DYRK1A; TTBK1; and P70S6 kinase [43,89–99]. These experiments
assisted in determining which kinases phosphorylate which phospho-
epitopes of tau and whether there is a sequential phosphorylation ofsites, such as for phosphorylation of Thr231, Ser396, and Ser400 by
GSK-3β that depends on a previous phosphorylation of Ser235,
Ser400, and Ser404, respectively, to provide one example [100,101]. A
few of these candidate kinases have been expressed in transgenic
mice and tau phosphorylation has been analyzed, either in single-
transgenic mice or after crossbreeding with tau transgenic mice. The
ﬁndings conﬁrmed that kinases play an important role in NFT
formation and neurodegeneration. The bulk of studies concentrated
on two kinases, GSK-3β and Cdk5, as outlined below.
The kinase GSK-3β is inactivated by phosphorylation of residue
Ser9. Mice with a constitutive active S9A form of GSK-3β showed
increased activity, in the absence of neuroﬁbrillary pathology.
Interestingly, crossing of these mice with human wild-type tau
transgenic mice markedly improved the axonopathy and motor
deﬁcits that characterize the latter strain [102]. These ﬁndings would
therefore suggest that GSK-3β is protective. However, additional
studies using different models reached the opposite conclusion.
When mice with an inducible expression of GSK-3β were crossed
with mice that express tau with three FTDP-17 mutations combined
(VLW mice), the double-transgenic mice developed thioﬂavin S-
positive tau aggregates and tau ﬁlaments. Moreover, the atrophy of
the dentate gyrus of the hippocampus, which was present in the
single-transgenic GSK-3β mice, was accelerated in the double-
transgenic mice [103]. To explore whether the phenotype resulting
from increased GSK-3β activity could be reverted following restora-
tion of normal GSK-3β levels, transgene expression was shut down in
symptomatic mice. This led to normal GSK-3β activity, normal
phospho-tau levels, diminished neuronal cell death, and suppression
of the cognitive deﬁcits [104]. When an inducible system was used to
express a dominant negative mutant form of GSK-3β, this caused
apoptosis and a reversible motor deﬁcit [105]. In these mice, AT8
phosphorylation (pSer202/pThr205) was reduced by 72% and PHF-1
phosphorylation (pSer396/pSer404) by 46%. So in conclusion, these
data identify GSK-3β as a tau kinase in vivo.
Another kinase that has been expressed in transgenicmice is Cdk5.
To address its role in tau pathogenesis, P301L tau transgenic JNPL3
mice were crossed with mice transgenic for the Cdk5 activator p25,
the latter being expressed under control of the NSE promoter. This
caused a ﬁvefold increase in NFT numbers in double-transgenic mice,
along with hyperphosphorylation of tau at the putative cdk5 epitopes
pThr181 (AT270), pSer202, pThr231, and pSer396/pSer404 (AD2/
PHF-1) [106]. On the other hand, a p25-mediated overactivation of
Cdk5 in a CaMKII promoter-driven p25 transgenic strain did not
induce tau hyperphosphorylation at a young age per se, possibly
because Cdk5 overactivation inhibited GSK-3β, by phosphorylating its
inhibitory Ser9 site [107]. However, as the mice became older, this
inhibition was lost, resulting in increased GSK-3β activity that was
associated with tau hyperphosphorylation at the AT8 (pSer202/
pThr205) and PHF-1 (pSer396/pSer404) sites. Together with phar-
macological and co-immunoprecipitation experiments this would
suggest that GSK-3β is a key mediator of tau hyperphosphorylation,
while Cdk5 acts as a modulator of tau hyperphosphorylation via the
inhibitory regulation of GSK-3β [107]. These ﬁndings were conﬁrmed
in a second p25 transgenic model [108]. It was found that
phosphorylation of residue Ser9 of GSK-3β was mediated by an
enhanced activity of the neuregulin receptor complex, ErbB, and by
activation of the downstream phosphatidylinositol 3 kinase/Akt
pathway. While young p25 mice had elevated Aβ levels, levels of
phosphorylated tau were decreased. Thus, Cdk5 appears to play a
dominant role in the regulation of amyloidogenic APP processing,
whereas GSK-3β seems to play a dominant role in overall tau
phosphorylation [108].
Inducible systems were employed that caused pronounced
phenotypic changes. For example, transgenic mice with an inducible
p25 expression in the postnatal forebrain revealed a massive
neuronal loss in the cortex and hippocampus, along with forebrain
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of age, endogenous tau was hyperphosphorylated at many epitopes,
as shown for AT8 (pSer202/pThr205) and PHF-1 (pSer396/
pSer404). In 1-year-old mice, immuno-electron microscopy of
sarkosyl-insoluble fractions revealed tau ﬁlaments that were phos-
phorylated at the AT8, PHF-1, TG3 (pThr231/pSer235), and AT100
(pThr212/pSer214) epitopes. Also, Gallyas silver impregnation
revealed NFT formation in these mice [109]. In a second inducible
mouse strain, neuronal p25 triggered a similar neurodegeneration
and marked neuronal loss, causing brain atrophy with a 40% loss at 5
months of age resulting in an almost complete elimination of the
hippocampus. Interestingly, this type of neurodegeneration was not
associated with hyperphosphorylation of tau or Aβ generation [110].
One likely explanation is that p25 neurotoxicity is related to
substrates other than tau or APP.
The tau-tubulin kinase (TTBK) family consists of TTBK1 and TTBK2
that belong to the casein kinase 1 superfamily. Different from TTBK2,
TTBK1 is speciﬁcally expressed in neurons. It can phosphorylate tau
directly at multiple Ser/Thr residues that are found in PHF-tau in AD
brain. Furthermore, TTBK1 is expressed in NFT-bearing neurons in the
AD cortex [99]. Transgenic mice expressing full-length human TTBK1
show an age-dependent memory impairment accompanied by
increased phosphorylation of tau and neuroﬁlaments, and increased
levels of p25 and p35 [111].
Finally, another interesting kinase is DYRK1A (dual speciﬁcity
tyrosine-regulated kinase-1A) that has been implicated in Down's
syndrome (DS), due to the location of the Dyrk1a gene in the critical
region of human chromosome 21 [96]. DS is a genetic disorder in
humans caused by partial or complete trisomy of chromosome 21.
People with DS show a tendency towards premature aging and an
increased risk for AD [112]. DS patients show an early-onset
tauopathy that resembles AD in many ways. In addition to mental
problems, motor dysfunction is highly prevalent in DS. Dyrk1a
transgenic mice express the transgene in several areas of the mid-
and hindbrain [113]. When assessed in motor tests such as the
treadmill, the mice showed impairment in some parameters; in
particular, they required longer training periods [113]. A transcrip-
tomic analysis revealed upregulation of the NMDA receptor subunit
2A which may explain the altered excitatory transmission reported in
humans with DS and in DS mouse models [114]. Altered synaptic
plasticity along with learning and memory deﬁcits was reported for a
second strain, that used a BAC clone of Dyrk1a [115]. A similar
memory phenotype was found in Dyrk1a haplo-insufﬁcient mice
[116]. In one of the mouse models, tau phosphorylation was
addressed: tau in Dyrk1a transgenic mice was hyperphosphorylated
at Thr212, Ser202, and Ser404; furthermore, phosphorylation by
DYRK1A strongly inhibited the ability of tau to promote microtubule
assembly [117]. The ﬁnding that gene dosage of Dyrk1 affects tau
splicing may explain the early-onset tauopathy in individuals with DS
[118].
While these studies always only test a subset of tau phosphory-
lation sites, they still highlight a role for cdk5 and its activator p25 in
Aβ pathology, and for GSK-3β, DYRK1A, and TTBK1 in tau aggregation.
Whether targeting a speciﬁc kinase in the development of an AD
therapy will be a fruitful approach is still a matter of debate. It may
well be that in a human setting a general subtle downregulation of
kinase(s) in the brain may be more beneﬁcial.
6. Tau phosphorylation in phosphatase transgenic mice
Of the serine/threonine-speciﬁc phosphatases that are abundant
in the brain, protein phosphatase 2A (PP2A) is a major phosphatase
implicated in tau dephosphorylation [119], perhaps more so because
PP2A can bind directly to tau [120–122]. PP2A is a trimeric
holoenzyme that consists of a catalytic subunit C and a scaffolding
subunit A. The A/C core enzyme associates with variable regulatorysubunits of the PR55(B), PR56/61(B′), PR59/72/130(B″), and PR93/
110(B″′) families to form heterotrimers [123]. Recruitment of
regulatory B subunits into the holoenzyme is dependent upon the
highly conserved DYFL motif in the carboxy-terminus of subunit C
that undergoes methylation at Leu309, thereby affecting subunit B
recruitment [124,125]. The resolution of the structure of the B subunit
provides signiﬁcant insight into how PP2A dephosphorylates tau
[126]. Interestingly, methylation of the C subunit does not seem to be
required for in vitro assembly of the PP2A holoenzyme involving
either B or B′. The authors argue that the regulatory subunits may be
sequestered in a speciﬁc cellular compartment and that the
methylated carboxy-terminus of the C subunit may allow subcellular
targeting for holoenzyme assembly [126].
Dephosphorylation of tau can be blocked in cells by okadaic acid
(OA), an inhibitor of the two phosphatases PP1 and PP2A [127,128].
When rat brain slices were incubated with OA, tau became
phosphorylated at multiple sites [129]. A role for PP2A in AD is
implicated by the ﬁnding that its activity is reduced in AD brain [130];
furthermore, association analyses indicate that a CAG repeat poly-
morphism in one of the B subunits may confer susceptibility to AD
[131].
Transgenic strategies targeting PP2A include gene knockouts,
overexpression of regulatory subunits, and dominant negativemutant
approaches [132]. A knockout of the major catalytic subunit Cα
caused delayed embryonic lethality [133], as the highly homologous
Cβ subunit failed to complement the lack of Cα in mesoderm
formation [134], due to a different subcellular localization of the
two catalytic subunits [135]. Under physiological conditions, the A
and C subunits are ubiquitously expressed, whereas the regulatory B
subunits show a tissue-speciﬁc expression; they also reveal a
differential expression pattern in brain and during neuronal differ-
entiation [136–138].
To address the role of PP2A in tau phosphorylation in vivo,
transgenic mice were generated that express a dominant negative
mutant form of the catalytic subunit Cα of PP2A, L199P, in neurons.
The transgenic mice have a reduced PP2A activity resulting in a pre-
NFT phenotype, with phosphorylation of endogenous murine tau at
the AT8 (pSer202/pThr205) and Ser422 epitopes [139]. This effect
may be directly mediated by PP2A, but could also occur indirectly, via
deregulated kinases such as ERK and JNK, that are themselves
substrates of PP2A [140]. The carboxy-terminal DYFL motif of the
catalytic subunit has a role in the recruitment of B subunits into the
PP2A complex, by methylating leucine 309 and phosphorylating
tyrosine 307 [123]. To determine the role of the DYFL motif in PP2A
activity in vivo, a second dominant negative mutant strain was
established that expressed the L309A mutant form of Cα in neurons.
This caused an altered subunit composition of the PP2A holoenzyme
in vivo. In the brain, tau was hyperphosphorylated at Ser202/
Thr205 (AT8/CP13); furthermore, there was an impaired dephos-
phorylation of the intermediate ﬁlament protein vimentin [141]. The
additional expression of the L309A transgene expression in the
Harderian (lacrimal) gland caused a delayed postnatal development
and hypoplasia of this gland, causing enophthalmos [142].
When the PP2A L309A mutant mice were crossed with P301L tau
mutant pR5 mice, this caused a sevenfold increased number of
hippocampal neurons that speciﬁcally phosphorylated the Ser422
epitope of tau. The double-transgenic mice showed eightfold
increased numbers of NFTs compared to pR5 mice, in agreement
with the previous ﬁnding that NFT formation is correlated with and
preceded by phosphorylation of tau at the Ser422 epitope [143]. The
critical role of the DYFLmotif in PP2A function, with particular regards
to the cytoskeleton, is further demonstrated by cell culture experi-
ments, which showed that expression of mutants such as L309Δ
induces a loss of microtubules [144]. As mentioned above, in addition
to methylation at the carboxy-terminal Leu309, phosphorylation at
Tyr307 also regulates PP2A function [123]. PP2A phosphorylated at
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entorhinal cortex and the hippocampus, brain areas where the
neuroﬁbrillary changes are initiated [145]. Together, these studies
demonstrate a crucial role for PP2A in tau phosphorylation. As many
kinases are themselves substrates of PP2A, the control of PP2A goes
beyond the reversible phosphorylation of its non-enzymatic sub-
strates. It would not be surprising to ﬁnd that targeting of PP2A, in
particular of its regulatory subunits, represents a valid means of
treating AD.
7. Tau phosphorylation in mice with an amyloid pathology
Tau phosphorylation is part of the phenotypic characterization of
APP mutant mouse models. In the following, we selected a few
examples to demonstrate how Aβ affects endogenous tau phos-
phorylation in vivo. For example, in one of the earliest reports of a
strong Aβ plaque-forming mouse model, the APP23 mice, increased
tau phosphorylation was found to parallel Aβ peptide deposition
[146]. APP23 mice have been thoroughly investigated, recently by
using 3D reconstruction techniques to determine how small Aβ
aggregates associated with the microvasculature lead to morpho-
logical and architectural alterations of the vasculature, thus resulting
in an altered local blood ﬂow [147]. Even more studies have been
conducted with the APP mutant mouse strain Tg2576 in which an
anti-Aβ treatment provided evidence for a slow seeding mechanism
preceding a rapid ﬁbrillogenesis in determining the extent of Aβ
deposition [148]. Formation of AT8 (pSer202/pThr205)-positive
dystrophic neurites was found to occur simultaneously with Congo
red-positive plaque development [149]. Oxidative stress seems to
play an important role in the Aβ pathology. Superoxide dismutase 2
(SOD2) is an enzyme which detoxiﬁes reactive oxygen species that
are produced predominantly by mitochondria. Mice lacking SOD2
die within the ﬁrst week of life, and develop a complex heteroge-
neous phenotype arising from mitochondrial dysfunction and
oxidative stress [150]. By crossing the Tg2576 mice onto an SOD2
heterozygous knockout background, it was found that this mito-
chondrial SOD2 deﬁciency both exacerbated Aβ plaque burden and
tau phosphorylation at Ser396 [151].
Combinatorial approaches were particularly helpful in elucidating
the role of Aβ in tau phosphorylation and aggregation. When P301L
tau transgenic JNPL3 mice were crossed with Aβ plaque-forming
Tg2576mice, a sevenfold increase in NFT induction was seen [152]. In
a parallel study with P301L tau transgenic pR5 mice, we found that
stereotaxic injections with Aβ42 ﬁbrils caused a ﬁvefold increase in
NFT formation compared to uninjectedmice [153]. NFT formationwas
tightly correlated with phosphorylation of tau at Ser422 and AT100
(pThr212/pSer214), but not the AT8 (pSer202/pThr205) epitope.
Mutagenesis of phospho-sites in a human SH-SY5Y tissue culture
system revealed that the Ser422 epitope is required for the Aβ-
mediated formation of tau ﬁlaments [154–156]. Aβ further exacer-
bates a mitochondrial dysfunction that characterizes the pR5 mice
[157,158]. In a third study, Aβ plaque and NFT pathology was
combined in a single animal by a triple transgenic approach [159]. In
these 3xtg-ADmice (that express P301L mutant tau as well as mutant
APP and PS1), synaptic dysfunction, including deﬁcits in long-term
potentiation, was found to precede Aβ plaque and NFT formation. The
mice showed a remarkable phosphorylation pattern in that AT8
(pSer202/pThr205) staining was only evident after 6 months and
PHF-1 (pSer396/pSer404) only at around 18 months of age, as shown
for the hippocampus and cortex, despite a markedly high transgene
expression and prominent HT7 (human tau) reactivity [160]. In a
follow-up of the stereotaxic injection approach, Bolmont and
colleagues diluted brain extracts from aged Aβ plaque-forming
APP23 transgenic mice and intracerebrally infused these in to young
P301L tau transgenic mice. They found that 6 months after the
infusion a tau pathologywas induced in the injected hippocampus butalso in brain regions well beyond the injection sites such as the
entorhinal cortex and amygdala, areas with neuronal projection to the
injection site [161]. This is similar to ﬁndings in pR5 mice where Aβ
while injected into the hippocampus and somatosensory cortex
induced NFT formation in the amygdala, an area with neuronal
projections to the injection site [153]. Together, this demonstrates
that Aβ can induce tau hyperphosphorylation and augment a pre-
existing tau pathology in mice.
8. Tau phosphorylation in ﬂies and worms
More recently, invertebrate species have gained considerable
attention. Despite their reduced complexity, they offer distinct
advantages compared to mice. The life span of both the nematode
Caenorhabditis elegans and the fruitﬂy Drosophila melanogaster is
short. Costs for maintenance are low, handling is relatively easy, mass
production is possible, and screening for mutations is simple. Also,
working with these two species does not need approval from animal
ethics committees.
Several of the genes that are implicated in AD pathogenesis have
been expressed in ﬂies and worms. For example, both wild-type and
FTDP-17 mutant human tau have been expressed in the ﬂy. These
reproduced key features of the human disease, including adult onset,
progressive neurodegeneration, enhanced toxicity of mutant tau,
accumulation of abnormal tau, and anatomical selectivity. Interest-
ingly, immunoreactivity for phospho-epitopes such as 12E8
(pSer262/pSer356), AT100 (pThr212/pSer214), and AT180
(pThr231/pSer235) increased as the ﬂies aged, whereas immuno-
reactivity using a phosphorylation-independent antibody was unal-
tered. Neurodegeneration, can occur without NFT formation [162],
which is consistent with studies in mice [80]. When wild-type human
tau was expressed in combination with Shaggy, the Drosophila GSK-
3β homolog and wnt signaling pathway component, this lead to a
neuroﬁbrillary pathology with tau ﬁlaments [163].
When going through the vast literature on animal models of AD, it
becomes obvious that most of the studies addressing the role of tau
phosphorylation in tau aggregation and neurodegeneration are
descriptive, although a few mutagenesis studies have been per-
formed. To address the role of distinct tau phosphorylation sites in
controlling tau neurotoxicity, a mutagenesis study was performed in
Drosophila which indicates that here, no single phosphorylation
residue plays a dominant role in controlling tau toxicity, but rather
that tau phosphorylation sites work in concert to promote neurotox-
icity in vivo [164].
The 12E8 epitope, located in the microtubule-binding domain of
tau, is a substrate of MARK [44,165]. Work in Drosophila showed that
the MARK homologue PAR-1 is a physiological tau kinase that plays a
central role in regulating tau phosphorylation and toxicity, without
promoting NFT formation [165]. Mutating the PAR-1 phosphorylation
site Ser262/Ser356 (12E8) by alanine substitution abolished tau
toxicity. When human tau was expressed in the Drosophila eye along
with either GSK-3β/Shaggy or Cdk5, this enhanced toxicity of tau
[166]. Lithium administration inhibited GSK-3β activity and thus
reduced tau phosphorylation but did not ameliorate tau-induced
toxicity, possibly reﬂecting high levels of tau expression [166].
Compared to Drosophila, the nematode is even easier to work with
[167]. What is unique to C. elegans is that wild-type adult worms
contain a constant number of 959 somatic cells. Not only is the cell
number constant but also the position of each cell. Moreover, the
worm is transparent and hence, it is easy to track cells and follow cell
lineages. The nervous system of an adult hermaphrodite C. elegans
consists of only 302 neurons that form approximately 7000 synapses.
Transgenic animals can be generated either using microinjection or
ballistic approaches [168]. Increasingly, C. elegans is employed for
studies into diabetes and AD. Regarding the latter, research currently
progresses along two lines: ﬁrstly the characterization of C. elegans
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human AD genes in C. elegans [167].
Expression of P301L and V337M mutant tau in C. elegans led to
behavioral, synaptic, and pathological abnormalities, and caused an
earlier and more severe phenotype than overexpression of wild-type
human tau. Substantial neurodegeneration followed by loss of
neurons occurred after insoluble tau began to accumulate. Tau was
phosphorylated at the PHF-1 (pSer396/pSer404), AT270 (pThr181),
and 12E8 (pSer262/pSer356) epitopes in both the soluble and
insoluble fraction, and at Ser422 and AT8 (pSer202/pThr205) only
in the soluble fraction. However, tau phosphorylation did not appear
to correlate with the severity of the phenotype [169]. The fact that
neurological symptoms were apparent before insoluble tau accumu-
lated indicates that toxicity does not depend on the formation of large
tau aggregates. To determine the role of tau phosphorylation in
disease more directly, a short, fetal isoform of human tau was
expressed, with a total of 10 serines and threonines replaced by either
glutamate (a so-called pseudophosphorylation or PHP construct) or
alanine [170]. Both wild-type and PHP tau induced a progressive age-
dependent phenotype of uncoordinated locomotion (unc) in the
absence of neuronal degeneration. In comparison, the alanine mutant
transgenic worms displayed a reduced survival and developed an
earlier unc phenotype, indicating that phosphorylation at these sites
alone is not the cause of the observed defects [170]. However, it is
difﬁcult to draw any conclusions with regards to the role of single
phospho-epitopes in pathogenesis, as in the PHP construct, 10 sites
were pseudophosphorylated simultaneously.
9. Implications of animal work for pathogenesis and therapy
Which phosphorylation sites are critical in triggering the cascade
of neuronal dysfunction and, eventually, neuronal loss in tauopathies?
What are the implications of data obtained in animal models for the
development of therapies? Obviously, the promiscuity of kinases and
phosphatases and the interdependence of phosphorylation sites,
along with a proﬁle that can differ from one neuron to the next,
renders it difﬁcult at present to pinpoint speciﬁc phosphorylation
sites and their regulation [171–173].
We have found in vivo that NFT formation is associated with the
phosphorylation of the pSer422 and pThr212/pSer214 (AT100)
epitope [153] (Fig. 1). This and additional studies including site-
directed mutagenesis of tau phosphorylation sites suggest a role for
speciﬁc phospho-epitopes and hence kinases and phosphatases in
tau aggregation and neuronal dysfunction [63,154,174,175]. Other
studies support the notion that a generally increased phosphoryla-
tion rather than phosphorylation of speciﬁc sites is needed
[156,164]. This concept is also supported by a recent analysis of
tau aggregation and the role of phosphorylation in this process in an
inducible N2a cell line that expresses ΔK280 full-length tau with and
without truncated forms of tau [176]. While this study is restricted
to 4R tau and needs to be validated in vivo, interestingly, aggregation
of full-length tau was found to be triggered by truncated fragments
and was associated with the phosphorylation of most of the few
sites analyzed. These were distributed between both soluble and
aggregated tau, suggesting that none of the sites determines
aggregation in an all-or-none manner [176]. Overall, whereas
phosphorylation in the repeat domain tends to inhibit aggregation,
other sites show a tendency to support aggregation. Together, this
has obvious implications for treatment strategies as it would imply
that phosphorylation in general, rather than speciﬁc tau kinases,
needs to be blocked [87].
Other take home lessons are that transgenic animal models prove
that expression of FTDP-17 mutant tau accelerates tau pathology,
causing NFT formation within the lifetime of mice. They underscore
the role of serine/threonine-speciﬁc phosphorylation in tau aggrega-
tion. Strong evidence has been provided for a role of the tau phospho-epitopes AT100 (pThr212/pSer214) and S422 in tau aggregation as
indicated above, although a map of “necessary” and “sufﬁcient”
epitopes of tau is still lacking. Based on the currently available data it
appears that phosphorylation of tau is closely linked to tau
aggregation and ﬁbril formation.
A tau-directed treatment strategy may target any step involved in
converting tau to a toxic species [177]. Alternatively, tau levels (and
hence levels of phosphorylated tau) may be altogether reduced as it
has been shown that Aβ toxicity is exerted via tau and that
excitotoxicity can be rescued when tau levels are reduced [178].
Several therapeutic strategies for treating AD on the basis of tau
hyperphosphorylation are available as has been discussed recently
[179]: these include (1) inhibition of GSK-3β, Cdk5 and other tau
kinases; (2) restoration of PP2A activity; and (3) targeting O-
glycosylation of tau [179].
A more recent study evaluated the concept of the promiscuity of
kinases by using an orally bioavailable and blood–brain barrier (BBB)-
penetrating analog of the relatively non-speciﬁc protein kinase
inhibitor K252a [180]. This compound prevented motor deﬁcits in
the P301L tau transgenic mouse line JNPL3 and reduced levels of
soluble aggregated hyperphosphorylated tau. Interestingly, NFT
numbers were not reduced, suggesting that the main cytotoxic effects
of tau are not exerted by NFTs, but by lower molecular mass
aggregates. This ﬁnding is in line with studies where a reduction in
the expression of transgenic human P301L tau led to a recovery of
memory function and stabilization of neuron numbers, despite the
continued accumulation of NFTs [80].
In many studies the GSK-3β inhibitor lithium has been evaluated.
For example, in 3xtg-AD mice that develop both plaques and tangles,
lithium chloride reduced tau phosphorylation but did not signiﬁcantly
alter the Aβ load [181]. In a second mutant human tau transgenic
mouse model, treatment with lithium chloride resulted in a
signiﬁcant inhibition of GSK-3 activity. After normalization to total
levels of tau, lithium chloride treatment was found to result in a
signiﬁcantly decreased phosphorylation at putative GSK-3-directed
sites, including pSer202 (CP13) and pSer396/pSer404 (PHF-1).
Phosphorylation at sites not recognized by GSK-3 such as pSer422
or pSer262 appeared not to be affected. There were signiﬁcantly
reduced levels of aggregated, insoluble tau. Administration of another
GSK-3 inhibitor also correlated with reduced insoluble tau levels,
supporting the idea that lithium exerts its effect through GSK-3
inhibition. Levels of aggregated tau correlated strongly with the
degree of axonal degeneration, and lithium chloride-treated mice
showed less degeneration when administration was started during
early stages of NFT development [182]. Very recently, a zebraﬁsh
model has been established which reproduced tau hyperphospho-
rylation, NFT formation, neuronal and behavioral disturbances, as well
as cell death. Of the many inhibitors of GSK-3β tested in the ﬁsh
model, a compound called AR-534 turned out to reduce tau
hyperphosphorylation in vivo, without causing toxic side-effects
[183].
Furthermore, the protein kinase inhibitor rapamycin has been
reported to reduce toxicity in Drosophila expressing either wild-type
or mutant forms of tau, probably by reducing the amount of insoluble
tau [184]. Rapamycin induces autophagy through inhibition of the
protein kinase mammalian target of rapamycin (mTOR) [185]. It
remains to be seen whether the beneﬁcial effects of rapamycin are
related to TOR-dependent abnormal cell cycle activation that has been
described in Drosophila tauopathy models.
While these data encourage the use of kinase inhibitors, at the
same time, microtubules, known to be stabilized by tau, have also
emerged as a drug target, as they can be strengthened by drugs such
as paclitaxel [186]. Which of the approaches will be translated into
human practice remains to be seen. As selective vulnerability
characterizes the AD brain, different brain areas may be differently
susceptible to any of these treatments [187].
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